DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization

Inclusion Criteria: * Men and women of 30-75 years of age. * Evidence of acute non-ST elevation myocardial infarction (NSTEMI) at screening, as confirmed by all of the following: * ECG transient ST-segment deviation/depression (≥ 1 mm) or prominent T-wave inversion, in multiple precordial leads; * Positive plasma biomarkers of myocardial necrosis: cardiac troponin I (cTnI); * Clinical symptoms of chest discomfort/pain or anginal equivalent (dyspnea, diaphoresis, excessive vomiting in diabetic patients and arm or jaw pain). * High risk subjects, defined as having Thrombolysis in Myocardial Infarction (TIMI) score ≥ 4 * Subjects refuse to undergo reperfusion therapies, such as coronary artery-bypass surgery (CABG) or percutaneous coronary intervention (PCI) within the next six months. * Therapy with study medication can be started within 7 days after first presentation in the hospital. * Able to take oral medication. Exclusion Criteria: * For females of childbearing potential: pregnancy, breast-feeding, the intention of becoming pregnant. * ECG presentation of STEMI. * History of hemorrhagic stroke within the last 3 months. * Patients with seizure at the onset of stroke or with regular medication for seizure/epilepsy. * History of serious head injury within the last 3 months. * History of major surgery within the last 3 months. * Ongoing long term need for oral anticoagulants, antiplatelets, fibrinolytic, or antithrombotic agents, other than the study medication. * Having any implanted pacemaker or cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy defibrillators (CRT-D). * Clinically significant arrhythmias or atrioventricular conduction block greater than first degree. * Acute or chronic heart failure as defined by the New York Heart Association (NYHA) classification as functional Class IV. * Known severe LV dysfunction (EF ≤ 40 and EDD \> 55 mm). * Inadequate liver function: ALT \> 3 times upper limit of normal (ULN). * Inadequate renal function: serum creatinine ≥ 1.5 times upper limit of normal (ULN). * Uncontrolled hypertension (SBP \> 185 mmHg or DBP \> 110 mmHg). * Random plasma glucose ≥ 180 mg/dL and HbA1c ≥ 7.0% at Screening. * Moderate to high risk of bleeding, defined as those who have the CRUSADE bleeding score of \> 30. * Known or suspected allergy to any of study medications used in the study, including other lumbrokinase products. * Prior experience with DLBS1033 or other oral lumbrokinase products. * Clinical evidence of malignancies with survival period \< 1 year. * Any other disease which judged by the investigator could interfere with trial participation or trial evaluation. * Enrolled in other interventional protocol within 30 days prior to Screening.